Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drug delivery technologies. At the core of its business is the proprietary recombinant human hyaluronidase enzyme, rHuPH20, which enhances the subcutaneous delivery of injectable biologics, small molecules, and fluids. This technology enables the conversion of intravenous (IV) therapies into subcutaneous (SC) injections, offering significant benefits such as reduced administration time, improved patient convenience, and potentially lower healthcare costs. Halozyme's platform is utilized across a broad range of therapeutic areas, including oncology, immunology, and endocrinology. The company partners with leading pharmaceutical and biotechnology firms through licensing and collaboration agreements, allowing its technology to be integrated into a diverse portfolio of approved and investigational drugs. Key products and partnerships include those involving treatments for breast cancer, chronic lymphocytic leukemia, multiple sclerosis, primary immunodeficiency disorders, and various autoimmune diseases. Halozyme's strategic focus is on expanding the application of its ENHANZE® drug delivery technology, driving value through its partnerships, and advancing its own pipeline of therapies. This approach positions Halozyme as a key enabler of more efficient and patient-friendly drug administration within the global biopharmaceutical landscape.